Benzodiazepines in the treatment of children with epilepsy.
Atonic seizures, atypical absence seizures, myoclonic seizures, tonic seizures, and infantile spasms are among the most difficult to control in children. Certain 1,4-benzodiazepines may be effective against these seizure types. Thus, clonazepam has been shown to reduce the frequency of absence, atypical absence, myoclonic, atonic, and complex partial seizures in children. Furthermore, both clonazepam and nitrazepam have been shown to be effective in the treatment of infantile spasms. However, their usefulness is limited by a deleterious effect on neurologic function, particularly on cognition. Controlled studies in animals and in adult patients and volunteers have demonstrated that clobazam has less neurotoxicity than 1,4-benzodiazepines and, in addition, may possess a psychotropic effect. Uncontrolled studies of clobazam in children suggest that this drug may be effective in the treatment of partial seizures, startle-induced seizures, infantile spasms, and Lennox-Gastaut syndrome. We studied the effect of clobazam in children whose seizures were resistant to most other antiepileptic drugs. Mental retardation was present in 80% of the children, and 62.5% had Lennox-Gastaut syndrome. Tolerance to clobazam developed in approximately one-third of patients, but this was frequently only partial and often responded to an increase in dosage. Of 50 children studied for a minimum of 3 months, seizures were controlled completely in 10 and frequency of seizures was reduced by more than 50% in a further 17. In most cases, parents observed a striking improvement in neurologic function, particularly in alertness, concentration, and balance. Thus, clobazam may be of value in the treatment of those seizures which are most difficult to control in children.
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000378:metabolism / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D000078306:Clobazam; D002998:Clonazepam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D003975:Diazepam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D004361:Drug Tolerance; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008140:Lorazepam / Q000627:therapeutic use; D009567:Nitrazepam / Q000009:adverse effects / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; D000078306:Clobazam; D002998:Clonazepam; D009567:Nitrazepam; D008140:Lorazepam; D003975:Diazepam